1. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
2. Atkins MB, Lotze M, Wiernick P, et al: High-dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma. Proc Am Soc Clin Oncol 16:494a,1997 (abstr 1780)
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690,1999-1695,
4. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
5. Chapman PB, Morrissey D, Ibrahim J, et al: Eastern Cooperative Oncology Group phase II randomized adjuvant trial of GM2-KLH + QS21 (GMK) vaccine high dose interferon-alfa 2b (HD IFN) in melanoma (MEL). Proc Am Soc Clin Oncol 18:538A,1999 (abstr 2078)+